NeoKare Nutrition Ltd is a leader in human milk-based formulations to meet the nutritional demands of the NICU’s.

Applying its patented human milk technology and leveraging 20 years’ experience in milk processing, NeoKare based in Worcestershire, UK is the first and only pharmaceutical grade, state-of-the-art manufacturing facility for human breast milk products in Europe. The site has multiple ISO 7 cleanrooms where all processing and packing occurs, onsite freezer (-200C) and R&D centre.

In the UK, between 52,0001 and 60,000 babies are born prematurely every year. Preterm birth is the leading cause of morbidity and mortality in neonates2 and optimal nutrition plays a critical role in a premature baby’s survival3.

NeoKare’s MMF is the world’s first and only powdered milk fortifier made from human breast milk, as opposed to bovine based products. NeoKare MMF meets the European Society for Paediatric Gastroenterology Hepatology and Nutrition’s (ESPGHAN) guidelines on energy content and protein content. Our advanced technology retains most of the oligosaccharides and other micro nutrients. NeoKare MMF is a hospital prescription product and cannot be purchased directly by consumers.

Feed About - NeoKare

As per the WHO Recommendations of 2017 on Newborn Health, VLBW infants who fail to gain weight despite adequate breast-milk feeding should be given human-milk fortifiers, preferably those that are human milk based.

NeoKare MMF when added to mothers’ milk provides the enhanced nutrition necessary for premature infants, as they have extra nutritional needs which cannot be provided by the mothers’ own. NeoKare MMF which is in powder form does not displace mothers milk.
Several research papers have acknowledged the benefits of an exclusive human milk diet, which is a human milk-based fortifier combined with mothers’ own or donor milk. An exclusive human milk diet has shown to reduce the rates of surgical NEC 4 and mortality, as well a reduction in late-onset sepsis, BPD, and ROP 5.

  • 2018 c.52,000 babies under 37 weeks – source: See also NICE which cites a premature birth rate of 8%, while the NHS cites an equivalent 1 baby in 13
  • Higgins RD, Devaskar S, Hay WW Jr, et al. Executive summary of the workshop "Nutritional Challenges in the High Risk Infant". J Pediatr. 2012;160(3):511-516. doi:10.1016/j.jpeds.2011.12.024.
  • Cristofalo EA, Schanler RJ, Blanco CL, et al. Randomized trial of exclusive human milk versus preterm formula diets in extremely premature infants. J Pediatr. 2013;163(6):1592-1595.e1. doi:10.1016/j.jpeds.2013.07.011
  • Hair AB, Peluso AM, Hawthorne KM, et al. Beyond Necrotizing Enterocolitis Prevention:Improving Outcomes with an Exclusive Human Milk-Based Diet [published correction appears in Breastfeed Med. 2017 Dec;12 (10 ):663]. Breastfeed Med. 2016;11(2):70-74. doi:10.1089/bfm.2015.0134

NHS based milk banks are doing a great service and NeoKare’s product seek to support and supplement the long-standing work done by these organisations. Mothers may also wish to consider donating their milk to